CME: Mepolizumab, an Additional Therapeutic Agent for Severe AsthmaAbstract. The challenging therapy of severe uncontrollable bronchial asthma aims primarily at sufficient symptom control and the minimization of the ...
Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic AsthmaAbstract. For patients with difficult-to-control, severe bronchial asthma, highly effective, targeted ...
Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic AsthmaAbstract. Abstract:For patients with difficult-to-control, severe bronchial asthma, highly ...